This week, there are 13 drugs in the patent and exclusivity list. They are: - GILEAD SCIENCES INC's BIKTARVY, containing active ingredient BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GILEAD SCIENCES INC's ODEFSEY, containing active ingredient EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE - GILEAD SCIENCES INC's VEMLIDY, containing active ingredient TENOFOVIR ALAFENAMIDE FUMARATE - GILEAD SCIENCES INC's GENVOYA, containing active ingredient COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GILEAD SCIENCES INC's DESCOVY, containing active ingredient EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - FRESENIUS KABI USA LLC's OMEGAVEN, containing active ingredient FISH OIL TRIGLYCERIDES - ANI PHARMACEUTICALS INC's VEREGEN, containing active ingredient SINECATECHINS - NOVARTIS PHARMACEUTICALS CORP's PROMACTA KIT, containing active ingredient ELTROMBOPAG OLAMINE Read More

This week, there are 4 drugs in the patent and exclusivity list. They are: - ASTRAZENECA AB's FARXIGA, containing active ingredient DAPAGLIFLOZIN - EAGLE PHARMACEUTICALS INC's RYANODEX, containing active ingredient DANTROLENE SODIUM - ULTRAGENYX PHARMACEUTICAL INC's DOJOLVI, containing active ingredient TRIHEPTANOIN - VIIV HEALTHCARE CO's RUKOBIA, containing active ingredient FOSTEMSAVIR TROMETHAMINE Read More

This week, there are 9 drugs in the patent and exclusivity list. They are: - JANSSEN PHARMACEUTICALS INC's INVOKAMET, containing active ingredient CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - JANSSEN PHARMACEUTICALS INC's INVOKAMET XR, containing active ingredient CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - JANSSEN PHARMACEUTICALS INC's INVOKANA, containing active ingredient CANAGLIFLOZIN - ASTRAZENECA AB's BYDUREON BCISE, containing active ingredient EXENATIDE SYNTHETIC - ASTRAZENECA AB's FARXIGA, containing active ingredient DAPAGLIFLOZIN - BOEHRINGER INGELHEIM's GILOTRIF, containing active ingredient AFATINIB DIMALEATE - EISAI INC's DAYVIGO, containing active ingredient LEMBOREXANT - NOVARTIS PHARMACEUTICAL CORP's AFINITOR DISPERZ, containing active ingredient EVEROLIMUS - ASTRAZENECA PHARMACEUTICALS LP's KOSELUGO, containing active ingredient SELUMETINIB SULFATE Read More

AstraZeneca has announced on June 12, 2024, that Farxiga (dapagliflozin) has been approved by the U.S. Food and Drug Administration (FDA) for improving glycemic control in children aged 10 years and above with type 2 diabetes (T2D). The FDA approval is based on the positive results from the Phase 3 Read More